Biomarkers in heart failure with preserved ejection fraction
Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preser...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Bohn Stafleu van Loghum
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796059/ |
| id |
pubmed-4796059 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-47960592016-04-08 Biomarkers in heart failure with preserved ejection fraction Meijers, W. C. van der Velde, A. R. de Boer, R. A. Review Article Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preserved ejection fraction (HFpEF). As a result, there is a scarcity of data describing the levels, dynamics, clinical and biochemical correlates, and biology of biomarkers in patients suffering from HFpEF, whereas HFpEF is in fact a very frequent clinical entity. This article discusses the value of different biomarkers in HFpEF. We describe various aspects of natriuretic peptide measurements in HFpEF patients, with a focus on diagnosis, prognosis and the risk prediction of developing heart failure. Further, we will discuss several emerging biomarkers such as galectin-3 and suppression of tumorigenicity 2, and recently discovered ones such as growth differentiation factor-15 and syndecan-1. Bohn Stafleu van Loghum 2016-03-04 2016-04 /pmc/articles/PMC4796059/ /pubmed/26942916 http://dx.doi.org/10.1007/s12471-016-0817-7 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Meijers, W. C. van der Velde, A. R. de Boer, R. A. |
| spellingShingle |
Meijers, W. C. van der Velde, A. R. de Boer, R. A. Biomarkers in heart failure with preserved ejection fraction |
| author_facet |
Meijers, W. C. van der Velde, A. R. de Boer, R. A. |
| author_sort |
Meijers, W. C. |
| title |
Biomarkers in heart failure with preserved ejection fraction |
| title_short |
Biomarkers in heart failure with preserved ejection fraction |
| title_full |
Biomarkers in heart failure with preserved ejection fraction |
| title_fullStr |
Biomarkers in heart failure with preserved ejection fraction |
| title_full_unstemmed |
Biomarkers in heart failure with preserved ejection fraction |
| title_sort |
biomarkers in heart failure with preserved ejection fraction |
| description |
Biomarkers are widely used and studied in heart failure. Most studies have described the utility and performance of biomarkers in sub-studies of randomised clinical trials, where the vast majority of the patients suffered from heart failure with reduced ejection fraction (HFrEF), and not with preserved ejection fraction (HFpEF). As a result, there is a scarcity of data describing the levels, dynamics, clinical and biochemical correlates, and biology of biomarkers in patients suffering from HFpEF, whereas HFpEF is in fact a very frequent clinical entity. This article discusses the value of different biomarkers in HFpEF. We describe various aspects of natriuretic peptide measurements in HFpEF patients, with a focus on diagnosis, prognosis and the risk prediction of developing heart failure. Further, we will discuss several emerging biomarkers such as galectin-3 and suppression of tumorigenicity 2, and recently discovered ones such as growth differentiation factor-15 and syndecan-1. |
| publisher |
Bohn Stafleu van Loghum |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4796059/ |
| _version_ |
1613553257368518656 |